title: Efficacy of extract of Pelargonium sidoides in children with acute non-group A beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double-blind, placebo-controlled trial.
abstract: BACKGROUND
  Clinical trial data suggest that antibiotics are not indicated for the treatment of acute non-group A beta hemolytic strep (non-GABHS) tonsillopharyngitis. Nevertheless patients are symptomatic and effective alternatives for its treatment are needed that have been evaluated in clinical trials.
  
  
  OBJECTIVE
  To confirm that treatment with an extract of Pelargonium sidoides (EPs 7630) is superior to placebo for the treatment of non-GABHS tonsillopharyngitis in children.
  
  
  METHODS
  Randomized, double-blind, placebo-controlled trial.
  
  
  METHODS
  Six study sites in 4 pediatric and ENT primary care outpatient clinics.
  
  
  METHODS
  One hundred forty-three children aged 6-10 years with non-GABHS tonsillopharyngitis present < or = 48 h, a negative rapid strep screen, a Tonsillopharyngitis Severity Score (TSS) > or = 8 points, and informed consent.
  
  
  METHODS
  EPs 7630 or placebo (20 drops tid) for 6 days.
  
  
  METHODS
  The primary outcome criterion was the decrease of the TSS from baseline (day 0) to day 4.
  
  
  RESULTS
  The decrease of the TSS from baseline (day 0) to day 4 was 7.1 +/- 2.1 points under EPs 7630 (n = 73), and 2.5 +/- 3.6 points under placebo (n = 70). The covariate adjusted decrease was 7.0 +/- 2.4 points under EPs 7630, and 2.9 +/- 2.4 points under placebo. The 95% RCI for the difference between the groups was [2.7; 4.9] demonstrating a significant difference in efficacy of EPs 7630 compared to placebo (P < 0.0001). Adverse events (AEs) occurred in 15/143 patients (EPs 7630: 4/73 patient, placebo: 44/70) and were not related to the investigational medication.
  
  
  CONCLUSIONS
  EPs 7630 was superior compared to placebo for the treatment of acute non-GABHS tonsillopharyngitis in children. Treatment with EPs 7630 reduced the severity of symptoms and shortened the duration of illness by at least 2 days.
authors.affiliation: Pediatric Department II, Academy for Continuing Medical Education, Kiev, Ukraine.
authors.forename: Viatcheslav V
authors.initials: VV
authors.lastname: Bereznoy
authors.forename: David S
authors.initials: DS
authors.lastname: Riley
authors.forename: Gernot
authors.initials: G
authors.lastname: Wassmer
authors.forename: Marianne
authors.initials: M
authors.lastname: Heger
mesh_terms: D000208:Acute Disease; D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D031316:Pelargonium; D010612:Pharyngitis / Q000188:drug therapy* / Q000382:microbiology; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013297:Streptococcus pyogenes; D013997:Time Factors; D014069:Tonsillitis / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome; D014455:Ukraine
chemical_list: D000900:Anti-Bacterial Agents; D010936:Plant Extracts